Paclitaxel / MAPK Cancer Research Results

PacT, Paclitaxel: Click to Expand ⟱

Features:

Paclitaxel (brand name Taxol) is a chemotherapy medication used to treat ovarian cancer, esophageal cancer, breast cancer, lung cancer, Kaposi's sarcoma, cervical cancer, and pancreatic cancer. Administered by intravenous injection.
Derived from a natural product, Taxol (from Pacific Yew Tree).
Paclitaxel is a drug (chemotherapy; a taxane). Its dominant anticancer mechanism is microtubule stabilization, which disrupts normal mitosis and drives mitotic arrest/stress signaling that can culminate in apoptosis.

Paclitaxel – Cancer Pathway Matrix

Rank	Pathway / Axis	Cancer / Tumor Context	Normal Tissue Context	TSF	Primary Effect	Notes / Interpretation
1	Microtubule stabilization → Mitotic arrest	Mitotic progression ↓; spindle dynamics impaired; cell division blocked	Proliferating normal cells affected	R, G	Core cytotoxic mechanism	Binds β-tubulin and stabilizes microtubules, preventing normal depolymerization required for mitosis.
2	Spindle assembly checkpoint activation	Prolonged mitotic arrest → mitotic catastrophe or apoptosis	Checkpoint stress in dividing tissues	R, G	Mitotic stress execution	Cell fate depends on whether arrest resolves via apoptosis or mitotic slippage.
3	Intrinsic apoptosis (mitochondrial pathway)	Caspase activation ↑; BAX/mitochondrial signaling engaged (context)	Limited unless stressed	G	Cell death execution	Often downstream of prolonged mitotic stress and mitochondrial perturbation.
4	ROS generation (secondary)	ROS ↑ (context-dependent); oxidative stress amplification	Oxidative stress possible in sensitive tissues	R, G	Stress amplifier	ROS rise appears secondary to mitotic and mitochondrial dysfunction; may enhance apoptosis.
5	Nrf2 antioxidant response (adaptive)	Nrf2 ↑ in some tumors; antioxidant buffering ↑; resistance potential	Protective antioxidant signaling	G	Adaptive resistance axis	Not a direct paclitaxel target; elevated Nrf2 may reduce drug sensitivity.
6	Drug resistance mechanisms	P-glycoprotein (MDR1) ↑; β-tubulin alterations; survival rewiring	—	G	Treatment failure driver	Efflux pumps and tubulin adaptations are major clinical resistance mechanisms.
7	Myelosuppression	—	Neutropenia risk ↑	G	Dose-limiting toxicity	Bone marrow suppression is a primary clinical constraint.
8	Peripheral neuropathy	—	Sensory neuropathy risk ↑	G	Dose-limiting toxicity	Likely related to microtubule disruption in axonal transport.

Time-Scale Flag (TSF):
P = 0–30 min (drug binding begins)
R = 30 min–3 hr (mitotic stress signaling, ROS changes)
G = >3 hr (apoptosis, resistance adaptation, tissue toxicities)

MAPK, mitogen-activated protein kinase: Click to Expand ⟱

Source: CGL-CS

Type:

Mitogen-activated protein kinases (MAPKs) are a group of proteins involved in transmitting signals from the cell surface to the nucleus, playing a crucial role in various cellular processes, including growth, differentiation, and apoptosis (programmed cell death).

MAPK Pathways: The MAPK family includes several pathways, the most notable being:
1.ERK (Extracellular signal-Regulated Kinase): Often associated with cell proliferation and survival.
2.JNK (c-Jun N-terminal Kinase): Typically involved in stress responses and apoptosis.
3.p38 MAPK: Associated with inflammatory responses and apoptosis.

Inhibitors: Targeting the MAPK pathway has become a strategy in cancer therapy. For example, BRAF inhibitors (like vemurafenib) are used in treating melanoma with BRAF mutations.
Altered Expression Levels:
Overexpression: Many cancers exhibit overexpression of MAPK pathway components, such as RAS, BRAF, and MEK. This overexpression can lead to increased signaling activity, promoting cell proliferation and survival.
Downregulation: In some cases, negative regulators of the MAPK pathway (e.g., MAPK phosphatases) may be downregulated, leading to enhanced MAPK signaling.
The expression levels of MAPK pathway components can serve as biomarkers for cancer diagnosis, prognosis, and treatment response. For example, high levels of phosphorylated ERK (p-ERK) may indicate active MAPK signaling and poor prognosis in certain cancers.

Numerous reports indicate that the MAPK pathway plays a major role in tumor progression and invasion, while inhibition of MAPK signaling reduces invasion.

Scientific Papers found: Click to Expand⟱

299-

ALA,

Cisplatin,

PacT,

Anti-cancer effects of alpha lipoic acid, cisplatin and paclitaxel combination in the OVCAR-3 ovarian adenocarcinoma cell line

in-vitro,

Ovarian,

OVCAR-3

MMP9↓, MMP11↓, MAPK↓,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:

Cell Death ⓘ

MAPK↓, 1,

Migration ⓘ

MMP11↓, 1, MMP9↓, 1,
Total Targets: 3

Pathway results for Effect on Normal Cells:

Total Targets: 0

Scientific Paper Hit Count for: MAPK, mitogen-activated protein kinase

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells